[3-[hydroxy-[2-[[4-(2-methoxyethoxy)-4-oxobutanoyl]amino]ethoxy]phosphoryl]oxy-2-[(E)-octadec-9-enoyl]oxypropyl] (E)-octadec-9-enoate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 英文名称: [3-[hydroxy-[2-[[4-(2-methoxyethoxy)-4-oxobutanoyl]amino]ethoxy]phosphoryl]oxy-2-[(E)-octadec-9-enoyl]oxypropyl] (E)-octadec-9-enoate
• 化学式: C₄₈H₈₈NO₁₂P
• 分子量: 902.2
• InChiKey: FAZMGEFNMFDAFQ-FRCMOREXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  12.7
• 重原子数：
  62
• 可旋转键数：
  49
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  173
• 氢给体数：
  2
• 氢受体数：
  12

反应信息

• 作为反应物：
  描述：

  、 Dotap 、 [3-[hydroxy-[2-[[4-(2-methoxyethoxy)-4-oxobutanoyl]amino]ethoxy]phosphoryl]oxy-2-[(E)-octadec-9-enoyl]oxypropyl] (E)-octadec-9-enoate 、 甘油三酸酯过氧化物 、 三硼三氢氧化物 在 甘油三酸酯过氧化物 、 N-[2-(Dimethylamino)ethyl]-2-(2-ethylbutoxy)-N-methyl-2,2-diphenylacetamide--hydrogen chloride (1/1) 作用下， 反应 33.0h， 生成 [1-(羟基-(2-羟基乙氧基)磷酰)氧基-3-[(E)-十八碳-9-烯酰基]氧基丙-2-基](E)-十八碳-9-烯酸酯
  参考文献：
  名称：

  Intracellular delivery of therapeutic agents

  摘要：

  本发明揭示了一种转导多肽（TP）-脂质体复合物的制备和使用方法，该复合物在脂质体的构成中含有一小部分带正电（阳离子）脂质，例如脂质体，可安全有效地将治疗剂，例如蛋白质、DNA、小分子和/或其他药物，递送到高等生物的细胞内，无论是体外还是体内。本发明的递送系统可以提高这些剂量的细胞内递送的效力，同时绕过内吞途径，同时最小化递送系统对接受细胞的毒性。

  公开号：

  US20050163832A1

文献信息

• Liposomes with enhanced circulation time and method of treatment
  申请人：Alza Corporation

  公开号：US20010051183A1

  公开（公告）日：2001-12-13

  A liposome composition for localizing an anti-tumor compound to a solid tumor via the bloodstream. The liposomes, which contain the agent in entrapped form, are composed of vesicle-forming lipids and between 1-20 mole percent of a vesicle-forming lipid derivatized with hydrophilic biocompatible polymer, and have sizes in a selected size range between 0.07 and 0.12 microns. After intravenous administration, the liposomes are taken up by the tumor within 24-48 hours, for site-specific release of entrapped compound into the tumor. In one composition for use in treating a solid tumor, the compound is an anthracycline antibiotic drug which is entrapped in the liposomes at a concentration of greater than about 50 &mgr;g agent/&mgr;mole liposome lipid. The method results in regression of solid colon and breast carcinomas which are refractory to anthracycline antibiotic drugs administered in free form or entrapped in conventional liposomes.

  一种通过血液定位抗肿瘤化合物到实体肿瘤的脂质体组合物。这些脂质体包含被困在其中的药物，由成泡脂质和1-20摩尔百分比的被水亲和性生物相容性聚合物衍生的成泡脂质组成，并且具有在0.07和0.12微米之间的选择性大小范围。静脉注射后，脂质体在24-48小时内被肿瘤吸收，以便将被困住的化合物定点释放到肿瘤中。在一种用于治疗实体肿瘤的组合物中，该化合物是一种蒽环类抗生素药物，其浓度大于50微克药物/微摩尔脂质体脂质。该方法导致对于自由形式或被困在常规脂质体中的蒽环类抗生素药物无效的实体结肠和乳腺癌的退缩。
• Solid tumor treatment method and composition
  申请人：Liposome Technology, Inc.

  公开号：US05213804A1

  公开（公告）日：1993-05-25

  A liposome composition for localizing an anti-tumor compound to a solid tumor via the bloodstream. The liposomes, which contain the agent in entrapped form, are composed of vesicle-forming lipids and between 1-20 mole percent of a vesicle-forming lipid derivatized with hydrophilic biocompatible polymer, and have sizes in a selected size range between 0.07 and 0.12 microns. After intravenous administration, the liposomes are taken up by the tumor within 24-48 hours, for site-specific release of entrapped compound into the tumor. In one composition for use in treating a solid tumor, the compound is an anthracycline antibiotic drug which is entrapped in the liposomes at a concentration of greater than about 50 .mu.g agent/.mu.mole liposome lipid. The method results in regression of solid colon and breast carcinomas which are refractory to anthracycline antibiotic drugs administered in free form or entrapped in conventional liposomes.

  一种脂质体组合物，可通过血液流向实体肿瘤，将抗肿瘤化合物定位到肿瘤部位。这些脂质体包含被困于其中的药物，由形成囊泡的脂质和1-20摩尔％的与亲水性生物相容性聚合物衍生的形成囊泡的脂质组成，并具有在0.07和0.12微米之间的选择性大小范围。静脉注射后，肿瘤在24-48小时内吸收脂质体，以将被困药物定点释放到肿瘤中。在用于治疗实体肿瘤的一种组合物中，该化合物是一种蒽环类抗生素药物，其在脂质体中的浓度大于50微克药物/微摩尔脂质体脂质。该方法导致难以处理的自由形式或被困于传统脂质体中的蒽环类抗生素药物引起的实体结肠和乳腺癌的退化。
• Intracellular delivery of therapeutic agents
  申请人：Torchilin Vladimir

  公开号：US20050163832A1

  公开（公告）日：2005-07-28

  The preparation and use of a transducing polypeptide (TP)— lipid vesicle complex having a small proportion of positively charged (cationic) lipids in the make-up of the lipid vesicle, e.g., liposome, for safe and efficient intracellular delivery of therapeutic agents, such as proteins, DNA, small molecules and/or other drugs, into a cell of a higher organism, in vitro or in vivo is disclosed. The delivery system of the invention results in increased efficacy of intracellular delivery of such agents, bypassing the endocytotic pathway of intracellular delivery while at the same time minimizing the toxicity of the delivery system towards the recipient cells.

  本发明揭示了一种转导多肽（TP）-脂质体复合物的制备和使用方法，该复合物在脂质体的构成中含有一小部分带正电（阳离子）脂质，例如脂质体，可安全有效地将治疗剂，例如蛋白质、DNA、小分子和/或其他药物，递送到高等生物的细胞内，无论是体外还是体内。本发明的递送系统可以提高这些剂量的细胞内递送的效力，同时绕过内吞途径，同时最小化递送系统对接受细胞的毒性。